CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS

12 Months Ended

Dec. 31, 2024

NOTE 16 – CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS

A condensed consolidating balance sheet of the Company as of December 31, 2024 follows:

	Yubo International Biotech Limited			Platinum (Cayman Island) and Platinum HK						Yubo		Yubo Beijing
	(Parent Company)			(Cayman Island)			Yubo Global			Chengdu (WFOE)		(VIE Subsidiaries)			Elimination			Consolidated

ASSETS
Total Current Assets	$	—		$	—		$	75,758		$	—	$	687,336		$	—		$	763,094
Investment in subsidiaries and variable interest entity (VIE)		(2,181,987	)		930,000			—			—		—			1,251,987			—
Intercompany receivables		—			—			428,573			—		552,274			(980,847	)		—
Other assets		—			—			21,132			—		750,307			298			771,737
Total Assets	$	(2,181,987	)	$	930,000			525,463			—		1,989,917			271,438			1,534,831
LIABILITIES AND SHAREHOLDERS' EQUITY

Total current liabilities	$	—		$	150,000		$	76,412		$	—	$	4,347,633		$	—		$	4,574,045
Intercompany payables		—			—			43,155			—		936,692			(979,847	)		—
Other liabilities		—			—			—			—		97,074			161,403			258,477
Total Liabilities		—			150,000			119,567			—		5,381,399			(818,444	)		4,832,522

Shareholders' Deficit:
Capital stock and additional paid in capital		—			1,569,229			853,550			—		2,040,922			(1,354,398	)		3,109,303
Accumulated deficit		(2,181,987	)		(789,229	)		(447,654	)		—		(5,851,907	)		2,609,965			(6,660,812	)
Accumulated other comprehensive income (loss)		—			—			—			—		292,730			(165,686	)		127,044
Non-controlling interests		—			—			—			—		126,774			—			126,774
Total Deficit		(2,181,987	)		780,000			405,896			—		(3,391,481	)		1,251,285			(3,297,691	)
Total Liabilities and Shareholders' Equity	$	(2,181,987	)	$	930,000		$	525,463		$	—	$	1,989,917		$	271,438		$	1,534,831

A condensed consolidating statement of operations of the Company for the year ended December 31, 2024 follows:

	Yubo International Biotech Limited			Platinum (Cayman Island) and Platinum HK						Yubo		Yubo Beijing
	(Parent Company)			(Cayman Island)			Yubo Global			Chengdu (WFOE)		(VIE Subsidiaries)			Elimination		Consolidated

Sales of product and services	$	—		$	—		$	—		$	—	$	3,470		$	—	$	3,470
Cost of goods and services sold		—			—			—			—		(822	)		—		(822	)
Gross profit		—			—			—			—		2,648			—		2,648
Total operating expenses		—			39,641			3,671			—		1,729,256			—		1,772,567
Loss from operations		—			(39,641	)		(3,671	)		—		(1,726,608	)		—		(1,769,919	)
Other income (expense)		—			—			(147	)		—		(211,725	)		—		(211,872	)
Equity in net loss of subsidiaries and variable interest entity (VIE)		(1,628,906	)		—			—			—		—			1,628,906		—
Net Loss	$	(1,628,906	)	$	(39,641	)	$	(3,818	)	$	—	$	(1,938,333	)	$	1,628,906	$	(1,982,792	)

Yubo International Biotech Ltd 10-K